Dr. Reddy's Laboratories Limited Cost of Revenue 2011-2026 | RDY

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Dr. Reddy's Laboratories Limited

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
86.6 B	80.6 B	70.4 B	65.7 B	62.5 B	62.4 B	-	-	-	-	-

All numbers in INR currency

Indicator range from annual reports

Maximum	Minimum	Average
86.6 B	62.4 B	71.4 B

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
BioNTech SE BNTX	2.91 B	$ 97.54	2.14 %	$ 27.2 B	Germany
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Evogene Ltd. EVGN	767 K	$ 0.81	-0.07 %	$ 27.9 M	Israel
Amphastar Pharmaceuticals AMPH	364 M	$ 20.47	0.49 %	$ 957 M	USA
Grifols, S.A. GRFS	2.97 B	$ 8.19	-0.24 %	$ 6.83 B	Spain
GT Biopharma GTBP	57 K	$ 0.36	-2.82 %	$ 1.98 M	USA
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
Halozyme Therapeutics HALO	229 M	$ 67.06	-1.12 %	$ 8.04 B	USA
Adverum Biotechnologies ADVM	100 K	-	-	$ 86.2 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Harmony Biosciences Holdings HRMY	198 M	$ 28.69	-0.69 %	$ 1.65 B	USA
Akebia Therapeutics AKBA	39.5 M	$ 1.41	0.71 %	$ 363 M	USA
Aquestive Therapeutics AQST	18.6 M	$ 4.16	1.84 %	$ 445 M	USA
Arcutis Biotherapeutics ARQT	36.7 M	$ 24.01	-0.85 %	$ 3.05 B	USA
ImmuCell Corporation ICCC	16.2 M	$ 7.12	1.14 %	$ 64.3 M	USA
AIkido Pharma AIKI	145 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	200 K	$ 32.24	-	$ 2.14 B	USA
Autolus Therapeutics plc AUTL	96.4 M	$ 1.48	-0.67 %	$ 394 M	Britain
Incyte Corporation INCY	372 M	$ 94.86	-1.26 %	$ 18.5 B	USA
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	20.6 M	$ 2.61	2.35 %	$ 16.4 M	USA
AstraZeneca PLC AZN	12.4 B	-	-	$ 96.9 B	Britain